Finance

Lists
Q4 2026 earnings • released • EPS miss -1.20% • Revenue miss -39.67%
See results
ARWR:NASDAQ
Arrowhead Pharmaceuticals Inc
$44.83
-6.17%
(-2.95) 1D
Nov 16, 3:14:14 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARWR...
Open
$47.12
High
$47.40
Low
$44.38
Mkt. cap
6.34B
Avg. vol.
2.03M
Volume
1.02M
52-wk high
$95.49
52-wk low
$37.06
EPS
-$5.11
Beta
1.34
Shares outstanding
141.37M
No. of employees
1K
Open
$47.12
High
$47.40
Low
$44.38
Mkt. cap
6.34B
Avg. vol.
2.03M
Volume
1.02M
52-wk high
$95.49
52-wk low
$37.06
EPS
-$5.11
Beta
1.34
Shares outstanding
141.37M
No. of employees
1K
News stories
From web sources and news partners
Profile
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
About Arrowhead Pharmaceuticals Inc
CEOChristopher Richard Anzalone
Employees1.06K
FoundedJan 1, 2004
HeadquartersPasadena, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 12 analysts giving stock ratings to ARWR in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ARWR in the last 3 months.
Highest
Current $44.83
$126.00 (+181.06%)
Average
$106.89 (+138.43%)
Lowest
$74.00 (+65.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/13/2026
Luca Issi
RBC Capital
Buy
Reiterated
$100.00
+123.1%
11/13/2026
Michael Ulz
Morgan Stanley
Buy
Maintained
$106.00
+136.4%
11/13/2026
Unknown Analyst
UBS
Buy
Reiterated
$109.00
+143.1%
11/13/2026
James Condulis
Stifel Nicolaus
Buy
Maintained
$96.00
+114.1%
11/13/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$126.00
+181.1%
11/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$120.00
+167.7%
11/11/2026
Madison Elsaadi
B. Riley Securities
Buy
Maintained
$123.00
+174.4%
11/10/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
-
-
10/15/2026
Eric Joseph
Citi
Buy
Maintained
$108.00
+140.9%
10/14/2026
Joon Lee
UBS
Buy
Reiterated
$109.00
+143.1%
10/15/2026
Andrea Newkirk
Goldman Sachs
Hold
Initiated
$74.00
+65.1%
09/24/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/30/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$115.00
+156.5%
08/04/2026
William Pickering
Bernstein
Hold
Reiterated
$46.00
+2.6%
05/13/2026
Mani Foroohar
Leerink Partners
Hold
Maintained
-
-
03/26/2026
Last report
Nov 12, 2026
Fiscal period
Q4 2026
-$1.52 / -$1.50
-1.20%miss
Revenue / Est. (USD)
37.79M / 62.64M
-39.67%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
264.03M
73.74M
75.25M
37.79M
Cost of goods sold
-
-
-
1.80M
Cost of revenue
-
-
-
1.80M
Research and development expenses
173.52M
165.66M
191.21M
197.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.70M
49.34M
54.14M
274.80M
Operating expense
223.22M
215.00M
245.35M
472.62M
Total operating expenses
223.22M
215.00M
245.35M
474.42M
Operating income
40.81M
-141.26M
-170.09M
-436.63M
Other non operating income
277.00K
-1.61M
1.28M
4.03M
EBT including unusual items
28.27M
-137.56M
-178.90M
-435.71M
EBT excluding unusual items
28.27M
-156.56M
-178.90M
-435.71M
Income tax expense
29.00K
7.00K
11.00K
-6.83M
Effective tax rate
0.10%
-0.01%
-0.01%
1.57%
Other operating expenses
-
-
-
-
Net income
30.81M
-132.73M
-194.28M
-428.00M
Net profit margin
11.67%
-180.01%
-258.17%
-1,132.46%
Earnings per share
0.22
-0.93
-1.36
-1.52
Interest and investment income
9.69M
16.87M
16.94M
14.37M
Interest expense
-22.50M
-23.85M
-24.56M
-22.80M
Net interest expenses
-12.82M
-6.98M
-7.63M
-8.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
47.20M
-134.89M
-163.43M
-429.42M
Gain or loss from assets sale
-
-19.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps